Acute effect of glibenclamide upon red cell transglutaminase activity in diabetic patients.
The acute effect of glibenclamide, a hypoglycemic sulfonylurea, upon transglutaminase activity was investigated in 6 type II diabetic patients by perfusing 1 mg glibenclamide during 1 h. Blood samples were drawn 0, 10, 20, 30, 60 min during and 30 and 60 min after perfusion to determine insulin, glucose and transglutaminase activity. No significant modifications in plasma insulin, plasma glucose and transglutaminase activity in red cells was induced by glibenclamide perfusion. Nevertheless, glibenclamide induced a significant decrease (p less than 0.005) in transglutaminase activity after 20 min of perfusion (629.83 +/- 53.08 and 521.18 +/- 43.92, mean +/- SE, at 0 and 20 min). No correlation was observed between glucose or insulin plasma levels and transglutaminase activity.
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004705:Endocytosis / Q000187:drug effects; D004912:Erythrocytes / Q000201:enzymology*; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000097:blood; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000493:pharmacokinetics; D011503:Transglutaminases / Q000097:blood*
D001786:Blood Glucose; D007328:Insulin; D013453:Sulfonylurea Compounds; D011503:Transglutaminases; D005905:Glyburide